Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents

Patients with myelofibrosis (MF) often develop anemia and frequently become dependent on red blood cell transfusions. Results from a phase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) demonstrated that MMB treatment ameliorated anemia, which was unex...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Asshoff, Malte, Petzer, Verena, Warr, Matthew R., Haschka, David, Tymoszuk, Piotr, Demetz, Egon, Seifert, Markus, Posch, Wilfried, Nairz, Manfred, Maciejewski, Pat, Fowles, Peter, Burns, Christopher J., Smith, Gregg, Wagner, Kay-Uwe, Weiss, Guenter, Whitney, J. Andrew, Theurl, Igor
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2017
Предметы:
Red Cells, Iron, and Erythropoiesis
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693322/
https://ncbi.nlm.nih.gov/pubmed/28188131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-09-740092
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы